US investors back £2.5m Intelligent Fingerprinting round
Intelligent Fingerprinting, a Cambridge UK business developing what is felt to be the world’s first portable fingerprint-based drug screening device, has secured a further £2.5 million investment from private UK and US investors.
The funding will provide working capital to complete the development of the company’s first products and to begin manufacturing at its new custom-designed premises in Cambridge.
Dr Jerry Walker, the company’s chief executive officer (pictured above), said: “This timely new investment represents another step forward for our company. It allows us to finalise our revolutionary mobile drug screening technology for market and begin the manufacturing process to meet early demand for the first of our planned fingerprint-based products.”
Intelligent Fingerprinting secured initial investment in 2009 followed by the first round of funding from US investors in 2012. Prior to the latest announcement, the company had raised £5.73m of private investment in four years on top of the original seed funding of £0.5m.
It has also secured several government-funded grants, including a sizeable allocation from the EUREKA Eurostars Programme (administered by Innovate UK) and funding for pilot studies within the UK’s National Health Service and coroners’ services.
Intelligent Fingerprinting’s portable fingerprint-based technology promises to greatly simplify the way in which drug screening is carried out.
Sample collection takes five seconds and the analysis of fingerprint sweat to screen for multiple drugs of abuse takes fewer than 10 minutes.
The device has potential for use in a variety of drug screening situations including drug rehabilitation services, offender management, criminal justice and occupational health.